c-Met Inhibitor JNJ-38877605

**Semantic type:** Organic Chemical|Pharmacologic Substance

**Definition:** An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met, a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR).

**Synonyms:** - JNJ-38877605 - JNJ-38877605